National Comprehensive Cancer Network

Educational Events & Programs

OVERVIEW

Patients with cancer often have widely divergent care experiences from screening through survivorship. Differences in care delivery and outcomes may be due, in part, to varying patient needs and preferences according to age and stage of life; inconsistent implementation of guidelines, recommendations, and policies; and unintended age bias in health care. The National Comprehensive Cancer Network’s® (NCCN®) Virtual Patient Advocacy Summit will provide an opportunity for a varied group of stakeholders including patients, caregivers, providers, patient advocacy organizations, policymakers, and industry to thoughtfully discuss the importance of providing quality, effective, efficient, and accessible cancer care across the patient lifespan.

AGENDA*

*Topics subject to change.

SUPPORTERS

Supported by AbbVie, Adaptive, ADC Therapeutics, AmerisourceBergen, Apobiologix, Astellas, BeiGene, Ltd., bluebird bio, Dendreon Pharmaceuticals, Eisai Inc, EMD Serono, Exact Sciences, Exelixis, Foundation Medicine, Inc., GSK, Heron, Incyte Corporation, Janssen Oncology; Pharmaceutical Companies of Johnson & Johnson, Kite, a Gilead Company, Lilly, MorphoSys US, Inc., Regeneron Pharmaceuticals, Inc., Seattle Genetics, Servier, Sun Pharma Oncology, Taiho, Verastem Oncology. Supported by AstraZeneca through its NCCN Corporate Council Membership. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. Supported by an independent educational grant from Merck & Co., Inc. This activity was made possible by Pharmacyclics, an AbbVie Company.

As of August 26, 2020.

Access the Library of White Papers!

NCCN offers a broad library of white papers from previous summits that may be pertinent to your organization.

View Supporter Opportunities.